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Background
Chronic graft-versus-host disease is a common late complication of allogeneic hematopoietic
stem cell transplantation. Corticosteroids are the standard initial treatment. Second-line treat-
ment has not been well defined. We evaluated the effectiveness and safety of low doses of
alemtuzumab plus low doses of rituximab in the treatment of steroid-refractory chronic graft-
versus-host disease.
Design and Methods
Ten men and 5 women were prospectively included in the study. All patients received one cycle
of subcutaneous alemtuzumab 10 mg/day/3 days and intravenous rituximab 100 mg on Days
+4, +11, +18 and +25. The therapeutic response was measured on Days +30, +90 and +365 of
the protocol.
Results
Median age was 41 years. The main site involved was the oral mucosa (86.7%) followed by
the eyes (66.7%), liver (60%), skin (53%), lungs (13.3%) and intestinal tract (6.7%). The overall
response was 100% at Day +30 evaluation: 10 patients (67%) had partial remission, 5 (33%)
had complete remission. At Day +90 evaluation, 7 (50%) patients had partial remission, 4
(28%) had complete remission; 3 (21%) had relapsed chronic graft-versus-host disease and one
patient did not reach the evaluation time point. So far, 5 patients have reached the Day +365
follow-up evaluation; 2 (40%) had partial remission, 2 had complete remission and one expe-
rienced chronic graft-versus-host disease progression. Adverse effects were mainly infections in
67% of patients; these were all quickly solved, except for one patient who died from pneumo-
nia.  
Conclusions
This combination therapy appears to be an efficacious and safe treatment for steroid-refractory
chronic graft-versus-host disease. Longer follow up to determine the durability of response and
survival is required (ClinicalTrials.gov: NCT01042509).
Key words: alemtuzumab, rituximab, graft-versus-host disease, hematopoietic stem cell trans-
plant.
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Introduction
Chronic graft-versus-host disease (cGvHD) is a common
late complication of allogeneic hematopoietic stem cell
transplantation (allo-HSCT). It characteristically shows
clinical manifestations that resemble autoimmune disor-
ders. cGvHD may affect up to 60% of patients who under-
go HLA-identical allo-HSCT and survive beyond 100 days.
cGvHD affects a variety of organs, including the oral
mucosa, intestinal tract, liver, eyes, lungs, bone marrow,
muscles and frequently the skin.1,2 In many patients,
GvHD develops despite prophylactic treatment, which
often includes low doses of methotrexate combined with
cyclosporine; both GvHD and this combination treatment
often decreases the quality of life and increases morbidity
and mortality.3,4 The most common first-line treatment for
cGvHD is steroids in combination with cyclosporine or
another calcineurin inhibitor. For patients with steroid-
resistant cGvHD, second-line treatment is less well
defined due to the lack of clinical studies.5 There are
numerous single drugs or combination therapies that can
be used to treat steroid-resistant cGvHD, including cal-
cineurin inhibitors, pulses of high doses of methylpred-
nisolone, photopheresis, mycophenolate mofetil,
immunomodulating agents like thalidomide, azathioprine,
rituximab, hydroxychloroquine, imatinib, alemtuzumab,
thoracoabdominal irradiation, etc.5,6 However, most of
these treatments, such as rituximab, are classified at C-2
level (recommended second-line treatment), and com-
pounds like alemtuzumab are classified at C-4 level
(experimental, used only in clinical trials or individual
cases).5 Rituximab is a monoclonal anti-CD20 antibody
used for treating non-Hodgkin’s lymphoma and several
autoimmune diseases. Rituximab causes a rapid depletion
of pre-B and mature B cells which remain at low levels for
3-6 months.7 Some studies have demonstrated that ritux-
imab is effective for cGvHD treatment because B cells play
a role in its pathogenesis, especially in patients with
immune cytopenia and skin involvement.8 Alemtuzumab,
on the other hand, is an anti-CD52 IgG monoclonal anti-
body that demonstrates activity against B cells, T cells and
Natural Killer cells.9,10 Currently, alemtuzumab is mainly
used to treat B-cell chronic lymphocytic leukemia; howev-
er, this drug has also been used in conditioning regimens
for allo-HSCT, and several reports have shown that treat-
ment with this monoclonal antibody reduced the inci-
dence of both acute and chronic GvHD.11,12 Information is
limited on the use of alemtuzumab for cGvHD treatment
and there are only studies of small series and a few case
reports.13,14
A simultaneous depletion of both B cells and T cells may
be an optimal treatment strategy for cGvHD, gaining a
tighter control of the strong immune response driving
cGvHD pathophysiology. Acting on this rationale, we
prospectively analyzed the effect of low doses of subcuta-
neous alemtuzumab in combination with low doses of rit-
uximab on 15 steroid-refractory cGvHD patients. Our goal
was to determine the effectiveness and safety profile of
this biological combination therapy.
Design and Methods
The study protocol was approved by the local ethics committee
and all of the patients gave their written informed consent prior to
the procedure. Fifteen patients who received an allograft (Online
Supplementary Appendix) and had cGvHD, as defined by the 2005
NIH consensus criteria on the diagnosis and staging of cGvHD,
were prospectively included.2 These patients had steroid-refracto-
ry cGvHD, defined as progressive disease or lack of a response
despite treatment with prednisone at 1 mg/kg/day for at least four
weeks. Patients were excluded if they relapsed from their under-
lying disease, had active bacterial or viral infection, were pregnant,
HIV-positive, or tested positive for hepatitis C virus or hepatitis B
surface antigen. Screening for cytomegalovirus (CMV) was per-
formed on a serum sample and a CMV Pp65 antigenemia test prior
to drug administration; patients who tested positive were exclud-
ed. Patients’ characteristics are summarized in Table 1.
Graft-versus-host disease diagnosis and staging
cGvHD diagnosis was based on clinical manifestations and lab-
oratory test results according to the NIH consensus criteria on the
diagnosis and staging of cGvHD;2 the results were confirmed with
a biopsy when it was necessary to rule out other diagnoses.
Chronic GvHD was scored on 4 levels (0-3) according to the con-
sensus scoring system.2 cGvHD diagnosis was confirmed only
after drug reaction, infection and malignancy were excluded as the
cause of the clinical manifestations.
Study drug administration
At the time of entering the study, all of the 15 patients were
receiving cyclosporine A (CsA) and prednisone. When the patients
initiated alemtuzumab-rituximab treatment, the prednisone dose
was gradually decreased over the following 15 days and eventual-
ly stopped. The cyclosporine dose was reduced to 50% when
cGvHD complete remission was achieved, independently of CsA
serum levels. Alemtuzumab was administered subcutaneously on
cycle Days 1-3 at a dose of 10 mg/day. One 30 mg alemtuzumab
vial was used for each patient, and prophylactic medication was
not necessary. Rituximab was given intravenously on Days +4,
+11, +18 and +25 of one cycle at a total dose of 100 mg each day.
Prior to rituximab administration, paracetamol and chlorpheni-
ramine were administered as prophylactic pre-medication. The
planned duration of treatment was limited to one cycle.  All of the
patients received prophylaxis to prevent infection, which included
daily acyclovir 400 mg during ten days a month, trimethoprim-sul-
famethoxazole every 48 h and fluconazole 100 mg/day. Complete
blood cell count and a chemistry profile were performed every ten
days for one month and subsequently every four weeks. Infection
screening was performed only on patients who had clinical mani-
festations or laboratory test results suggesting an active infection. 
Response definition
There is no simplified method for quantification of a therapeu-
tic response to cGvHD. The therapeutic response was based on
the clinician’s assessment, patients’ self-report of symptom inten-
sity, laboratory results and functional status. The therapeutic
response was measured on Days +30, +90 and +365 of the proto-
col. Data obtained at each evaluation were compared to the basal
data. A complete response was defined as resolution of all mani-
festations related to cGvHD in a specific organ. Partial response
was defined as an improvement in at least 50% of the cGvHD
manifestations. Progression was defined as an increase in symp-
toms, signs or laboratory test abnormalities.  
Results
Fifteen consecutive patients with steroid refractory
cGvHD were included in this study. Median age was 41
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years (range 20-57 years). All 10 men and 5 women had
GvHD prophylaxis failure and did not respond to a com-
bination treatment with steroids and CsA.  Four patients
(27%) had acute GvHD and achieved remission with CsA
and prednisone; however, these patients eventually devel-
oped cGvHD after several months and were then included
in the study. Four patients had cGvHD for more than one
year, and 2 of these patients had avascular necrosis of the
femoral head that was related to the chronic use of
steroids. Most of the patients had 2 or more organs
involved including the oral mucosa (86.7%), eyes (66.7%),
liver (60%), skin (53%), lungs (13.3%) and intestinal tract
(6.7%). Alemtuzumab-rituximab therapy was initiated at
a median of 31 months (range 2-128 months) after cGvHD
diagnosis. Previous cGvHD treatments included CsA,
steroids and phototherapy (PUVA). Three patients
received alemtuzumab or rituximab as a single drug for
more than 60 days prior to inclusion on the protocol; none
of the patients responded to single drug treatment (Table
1). All of the patients included in this study completed the
therapeutic schedule with a median follow up of 232 days
(range 72-618). 
The overall response was 100% at the Day +30 evalua-
tion; 10 patients (67%) had partial remission, and 5 (33%)
complete remission (Online Supplementary Tables 1-3). For
the patients with complete remission, the CsA dose was
gradually decreased and ultimately stopped. For the
patients with partial remission, the CsA dose was reduced
to 50% of its initial value. Patient 4 had diarrhea grade 1
that disappeared at Day 11 of the protocol (Table 2). At
the Day +90 evaluation, 7 (50%) patients had a partial
response, 4 (28%) had a complete response, 3 (21%) had
relapsed cGvHD and one patient had not yet reached Day
90 post treatment. One patient (Patient 6) who had
achieved cGvHD partial remission had a leukemia relapse
(acute promyelocytic leukemia) and received a second
allo-HSCT; this patient achieved complete remission
without GvHD. Of the patients with relapsed cGvHD
who restarted steroid treatment, one received a second
cycle of alemtuzumab-rituximab treatment and achieved
a second partial remission (Patient 14), and 2 (Patients 3
and 13) received four monthly doses of 100 mg rituximab
and achieved complete remission (Table 2). Currently,
only 5 patients are available to evaluate the Day +365 fol-
low up; 2 of them (40%) have a partial response, 2 have a
complete response and one is in progression of cGvHD
(Table 2).
Acute side effects of alemtuzumab administration
occurred in only one patient who had fever and chills
after the third dose; these appeared 30 min after alem-
tuzumab administration and disappeared after adminis-
tration of acetaminophen. Acute side effects of rituximab
occurred in 7 patients during intravenous infusion of the
drug, including chills in 4, rash in 2 and fever in one
patient. Most of the side effects occurred during the first
rituximab infusion and disappeared after the infusion
velocity was decreased and 100 mg of hydrocortisone
was co-administered. The late side effects of the therapy
were mainly infectious, including laryngitis, sinusitis,
pneumonia, urinary tract infection and oral herpes sim-
plex virus infection in one patient each, bronchitis in 2,
and reactivation of cytomegalovirus in 3 patients; acute
promyelocytic leukemia relapse was observed in one
patient once he achieved complete cGvHD remission.
Patient 10 (Table 2) had grade 2 lung cGvHD manifested
by shortness of breath after walking on flat ground. This
symptom disappeared at Day 35 of the protocol.
However, this patient later had pneumonia and died at
protocol Day 142 with partial cGvHD remission. The iso-
lated infectious agent was identified as Rhodococcus equi.
The 3 patients with CMV infection responded well to val-
ganciclovir. 
Fourteen of the 15 patients are still alive at a median fol-
low up of 232 days (Figure 1). 
Alemtuzumab and rituximab effectiveness in cGVHD
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Table 1. Demographic characteristics of the patients.
Patient Age Sex Diagnosis Chimerism Acute GvHD Day of Months of Previous cGVHD
(%) (grade) cGVHD cGVHD† treatment
start*
1 38 M HL 94 No 657 3.4 P, CSA
2 48 M MM 95 Skin  (3) Mouth (1) 123 30.8 P, CSA
3 45 F CML 98 Mouth (1) 630 1.9 P, CSA
4 46 M CML 100 No 81 127.8 P, CSA
5 39 M AA 92 No 78 15.5 P, CSA
6 35 M AML 100 No 90 38.6 P, CSA
7 26 M ALL 100 No 105 42.1 P, CSA, ATB, RTB
8 41 F MF 100 No 192 28.7 P, CSA
9 48 F AA 99 No 578 4.8 P, CSA, ATB
10 53 M AML 100 No 121 31.6 P, CSA
11 57 F CML 100 Mouth (1) 941 80.4 P, CSA
12 30 M HL 80 No 105 15.0 P, CSA, ATB, RTB, PUVA
13 20 M AML 95 No 78 5.3 P, CSA
14 39 F CML 90 No 149 50.9 P, CSA
15 43 M AML 100 Skin (2) Liver (1) 172 77.3 P, CSA
*Days between stem cell transplantation and cGVHD start. †Months of cGVHD evolution at start of alemtuzumab-rituximab. HL: Hodgkin’s lymphoma; MM: multiple myeloma;
AML: acute myeloid leukemia; ALL: acute lymphoblastic leukemia; CML: chronic myeloid leukemia; AA: aplastic anemia; MF: mycosis fungoides; P: prednisone; CSA: cyclosporine;
ATB: alemtuzumab; RTB: rituximab; PUVA: psoralens (P) and then exposing the skin to UVA (long wave ultraviolet radiation). 
Discussion
Previous studies have shown that both alemtuzumab
and rituximab have therapeutic activity on different
immunological diseases, and both have been used in an
attempt to reduce the incidence of GvHD.15,16 However,
there have been no reports of a combination of these
drugs in the treatment of cGvHD. In a previous study, we
used alemtuzumab to treat 18 patients with acute GvHD
(aGVHD) who did not respond to high doses of steroids;
most of the patients (83%) demonstrated a complete or
partial response.13 Recently, Schub et al. obtained similar
results with 18 patients.15 Alemtuzumab treatment for
cGvHD has only been reported in small studies and a few
case reports. Ruiz-Argüelles et al. described a patient with
extensive cutaneous cGvHD that was resistant to numer-
ous lines of treatment; this patient was treated monthly
with alemtuzumab and achieved complete remission after
seven months.14 However, rituximab is more commonly
used for cGvHD treatment than alemtuzumab. Several
reports have described the efficacy of rituximab for treat-
ment of cGvHD-associated immune cytopenia and cuta-
neous manifestations.8 Teshima et al. described 7 cGvHD
patients who were treated weekly with a full 375 mg/m2
dose of rituximab for four weeks; the treatment improved
immune hemolytic anemia, thrombocytopenia, and mild
skin and oral lesions in most of the patients, but had no
effect on severe cutaneous or ocular manifestations.17
Most studies have shown an overall response between 43
and 83%.17-22 A meta-analysis by Kharfan-Dabaja et al.
reported an overall rituximab response of 66%, with
improvements mainly in the skin (60%), oral mucosa
(36%), hepatic (29%), gastrointestinal (31%) and pul-
monary lesions (30%).23
The optimal rituximab dose for immune-mediated
hematologic disorders has not been established. In most
studies, the doses are similar to those for non-Hodgkin’s
lymphoma.24 However, because the number of lympho-
cytes in cGvHD is expected to be lower, lower doses of
the monoclonal antibodies may be required. Zaja et al.
demonstrated that low-dose rituximab (100 mg weekly)
can produce significant and durable responses which are
associated with B-cell depletion in patients with autoim-
mune cytopenias.25,26 Thus, we assessed the therapeutic
benefit of a low-dose combination of subcutaneously
administered alemtuzumab and rituximab.
In our study, we used combined alemtuzumab-ritux-
imab to reduce both B- and T-lymphocyte activity and
reduce the clinical manifestations of cGvHD. This combi-
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Table 2. Outcome of therapy.
Patient End of 90 365 Chronic GvHD Maximal LAE FU Current
treatment days days (0-4)2 response status
s m/GI^ l e lu s m/GI^ l e lu
1 PR PR * 2 1 1 1 1 1 No 88 Alive
2 PR PR * 1 2 1 1 No 199 Alive
3 PR P† * 2 2 1 0 0 0 UTI 272 Alive
4 PR * * 2 1/1^ 2 2 1 0/0^ 0 2 No 72 Alive
5 CR PR PR 3 1 3 0 0 0 CMV 367 Alive
6 PR PR * 2 1 1 1 0 1 MDR 177 Alive
7 CR CR * 1 1 3 0 0 0 SI, HS 305 Alive
8 PR PR P‡ 3 1 2 1 0 2 CMV, LA 618 Alive
9 PR PR CR 2 2 0 0 BR 479 Alive
10 PR PR * 1 1 1 2 2 0 0 1 1 0 CMV, Pneu 142 Dead
11 CR CR * 2 0 No 232 Alive
12 CR CR * 2 2 1 0 0 0 No 286 Alive
13 PR P† * 1 2 1 1 1 1 No 197 Alive
14 PR P‡ PR 1 3 1 0 1 1 BR 411 Alive
15 CR CR CR 2 2 2 0 0 0 No 225 Alive
Chronic GVHD was scored in 4 levels (0-3) according to the consensus scoring system 2. *Point of evaluation not reached. †Received 4 doses of monthly rituximab, 100 mg achieving
complete remission. ‡Received a second cycle of alemtuzumab-rituximab achieving partial remission. PR: partial response; CR: complete response; P: progression; LAE: late adverse
event; FU: follow up in days; s: skin; m: mouth; GI^: gastrointestinal tract; l: liver; e: eye; lu: lung; UTI: urinary tract infection; sI: sinusitis; HS: herpes simplex, LA: laringytis, BR: bronchitis,
Pneu: pneumonia; MDR: malignant disease relapsed; CMV: cytomegalovirus. 
Figure 1. Overall survival of all patients.
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nation has previously been used to treat chronic lympho-
cytic leukemia.27 Furthermore, our group has successfully
used this combination to treat autoimmune cytopenias;
patients responded well and no toxicities were reported.28
In the present study, the maximal response occurred early
after patients finished their treatment with the drug com-
bination producing an overall response rate of 100% at the
Day +30 evaluation; 10 patients achieved a partial remis-
sion (67%) and 5 a complete remission (33%). The clinical
manifestations of cGvHD improved faster than expected;
this allowed us to stop prednisone treatment without
complications in all of the patients. The number of lym-
phocytes noticeably decreased at this point and slowly
increased over time. At the Day +90 evaluation, some
changes were observed in the response index. Three
patients with previous partial remission showed cGvHD
progression, despite a low lymphocyte count (< 500 K/μL);
however, these 3 patients responded well to a second
cycle of alemtuzumab-rituximab or to monthly rituximab
treatment, as described above. It is important to note that
cGvHD progression in these 3 patients may be related to
a decrease in alemtuzumab-rituximab therapeutic activity
and changes in the dose of immunosuppressive therapy.
This finding should form the basis for better strategies to
prevent GvHD progression.
Currently, 5 patients have survived 365 days for follow-
up evaluation; one showed cGvHD progression with skin
involvement indicated by pigmentary changes and sclerot-
ic lesions. The patient received a second alemtuzumab-rit-
uximab cycle and eventually achieved partial remission. 
Acute adverse events during alemtuzumab-rituximab
delivery were mild and quickly solved in all cases. Several
studies have indicated that alemtuzumab and rituximab
treatment predisposes the patient to opportunistic infec-
tions.15,29-33 Alemtuzumab has been associated with infec-
tions such as CMV, adenovirus and toxoplasmosis.15 Park et
al. reported a CMV infection rate of 41.6% and a 90%
CMV infection recurrence rate in 12 patients who received
an alemtuzumab-based conditioning regimen for allo-
HSCT.34 Treatment with rituximab has also been associat-
ed with viral and opportunistic infections; Kimby reported
a 30% incidence of infection in patients who received rit-
uximab.7 In our study, the incidence of infection was 67%;
however, most of the infections were grade 2 and were
resolved in an outpatient setting. One patient died from
pneumonia caused by a Rhodococcus equi infection; this is an
anaerobic, gram-positive coryneform bacterium that is an
opportunistic pathogen which mainly infects HIV-positive
patients.35 A number of additional factors in our patients
may predispose them to diverse infections. The ingestion
of additional medications, the effect of cGvHD, as well as
other medical problems may influence the patient’s
immune response. All of the patients included in this study
had previously been taking steroids and CsA over a long
period of time; this chronic immunosuppression may have
made the patients more susceptible to infection. 
In conclusion, low-dose alemtuzumab-rituximab com-
bination therapy appears to be an efficacious and safe
treatment for steroid-refractory cGvHD. Longer follow up
is needed to determine the durability of response and sur-
vival. Furthermore, additional low monthly doses of ritux-
imab may extend this response. Future studies assessing
the benefits of low or conventional doses of rituximab for
maintenance are needed to assess the long-term efficacy.
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